QQ客服 官方微博 反馈留言

	Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study
	Ye, L.; Chen, M.; Gao, X.; Wu, K.; Ran, Z.; Yang, H.; Liu, Z.; Cao, Q.
	2019
卷号	13页码:S353-S354
ISSN号	1873-9946
DOI	10.1093/ecco-jcc/jjy222.606
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6343535
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Ye, L.,Chen, M.,Gao, X.,et al. Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study[J],2019,13:S353-S354.
APA	Ye, L..,Chen, M..,Gao, X..,Wu, K..,Ran, Z..,...&Cao, Q..(2019).Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study.,13,S353-S354.
MLA	Ye, L.,et al."Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study".13(2019):S353-S354.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。